MANILA, Philippines — Stada Philippines Inc. and Sandoz Philippines Corp., pharmaceutical companies, have entered into an agreement wherein Stada Philippines will take over the local distribution rights for various important legacy medications previously handled by Sandoz Philippines.
This includes one antibiotic and two brand names for cardiovascular medications.
The Philippine branch of Germany’s Stada Arzneimittel AG announced on Thursday that it now holds complete responsibility for marketing the antibiotics Zinnat, the hypertension treatment Ambesyl, and the cholesterol-reducing medication Robestar.
READ: The US considers imposing duties on pharmaceuticals and semiconductors from the Philippines.
"We derive our essence from caring for people's well-being through the products we introduce to the market. Currently, we embody this mission as a reliable ally to Sandoz," stated Paolo Valenzuela, the general manager of Stada Philippines.
The pact became active on May 1, making Stada accountable for promoting, selling, and distributing these products.
During a subsequent interview with Axofa, Sandoz stated that prices would not rise after the agreement.
In the meantime, Nevin Gulbaz, the country manager for Sandoz Philippines, stated that this collaboration enables them to assist a greater number of patients.
READ: Drug company remains calm amid Trump's tariff moves